Last reviewed · How we verify
Screening for Flare After Discontinuation of Biological/Targeted Synthetic Disease Modifying Anti-rheumatic Drug (b/tsDMARD) in Rheumatoid Arthritis
To evaluate whether stringent follow-up consisting of combined laboratory and ultrasound surveillance is superior to clinical monitoring alone to maintain clinical remission in rheumatoid arthritis.
Details
| Lead sponsor | Medical University of Vienna |
|---|---|
| Phase | NA |
| Status | UNKNOWN |
| Enrolment | 85 |
| Start date | 2022-03 |
| Completion | 2024-09 |
Conditions
- Rheumatoid Arthritis
Interventions
- Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD)
Primary outcomes
- Proportion of subjects without a clinical flare until week 24 — week 24
Proportion of subjects without a clinical flare